Holen Sie sich die Stockscreener-App
53.88
0.37%
-0.20
Handel nachbörslich:
53.88
Schlusskurs vom Vortag:
$54.08
Offen:
$54.09
24-Stunden-Volumen:
10.70M
Relative Volume:
6.14
Marktkapitalisierung:
$4.31B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-14.37
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
+16.88%
1M Leistung:
+24.58%
6M Leistung:
+54.74%
1J Leistung:
+85.28%
1-Tages-Spanne:
$53.79
$54.09
1-Wochen-Bereich:
$45.17
$54.53
52-Wochen-Spanne:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
53.88 | 4.33B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-04 | Eingeleitet | TD Cowen | Buy |
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion - Indian Pharma Post
The week in pharma: action, reaction and insight – week to October 10 - The Pharma Letter
Akero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Akero Therapeutics' (AKRO) Peer Perform Rating Reiterated at Wolfe Research - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Cut to "Hold" at HC Wainwright - MarketBeat
Lifesci Capital Downgrades Akero Therapeutics (NASDAQ:AKRO) to Hold - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Insider Sells $576,000.00 in Stock - MarketBeat
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
Akero Therapeutics (NASDAQ:AKRO) Shares Gap UpShould You Buy? - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO) - GlobeNewswire Inc.
Akero Therapeutics Acquired by Novo Nordisk for $5.2B - The Globe and Mail
Akero Therapeutics (NASDAQ:AKRO) Cut to Hold at Jefferies Financial Group - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
Quantitative breakdown of Akero Therapeutics Inc. recent moveWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Akero Therapeutics Inc. stock bottoming outJuly 2025 Gainers & Pattern Based Trade Signal System - newser.com
Is Akero Therapeutics Inc. forming a bottoming baseJuly 2025 Outlook & Technical Pattern Based Buy Signals - newser.com
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
How to recover losses in Akero Therapeutics Inc. stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com
Novo Nordisk: New CEO Executing on Focused Strategy With Akero Acquisition - Morningstar Canada
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance? - Zacks Investment Research
Wolfe Research Downgrades Akero Therapeutics (AKRO) to Peer Perf - GuruFocus
Wolfe Research Downgrades Akero Therapeutics to Peer Perform From Outperform - MarketScreener
HC Wainwright Downgrades Akero Therapeutics to Neutral From Buy, $72 Price Target - MarketScreener
Novo makes bold $5.2bn bet on MASH treatment with Akero buy - BioXconomy
Akero: Novo Nordisk Acquisition Puts Focus On Unprecedented MASH Data With EFX (AKRO) - Seeking Alpha
Akero says new owner Novo Nordisk to drive commercialisation process - MarketScreener
Novo Nordisk analyst on Akero acquisition: Buys potentially best remedy for fatty liver - medwatch.com
Novo Nordisk to expand MASH portfolio with $5.2 Bn Akero Therapeutics buyout - ET Pharma
What drives Akero Therapeutics Inc 0K4 stock priceDividend Stability Analysis & Stocks With 200% Upside Potential - earlytimes.in
Is Akero Therapeutics Inc. (0K4) stock included in top ETFsBull Run & Verified Stock Trade Ideas - newser.com
Akero Therapeutics Inc. stock momentum explainedJuly 2025 Action & Momentum Based Trading Ideas - newser.com
Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger - MSN
Key facts: Novo Nordisk to Acquire Akero for $5.2 Billion; R&D Costs to Rise - TradingView
Novo Nordisk to Acquire Akero Therapeutics for $5.2B, Targeting Breakthrough Liver Drug - Azat TV
Akero Therapeutics Inc. (AKRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Akero therapeutics CSO sells $576k in shares - Investing.com
Akero Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AKRO - Benzinga
Novo Nordisk to acquire clinical-stage drugmaker Akero Therapeutics - MLex
Novo Nordisk’s Akero Bid Centered On Addressing Cirrhotic MASH - insights.citeline.com
Novo buys Akero for $4.7B in third and largest deal in key liver disease class - BioCentury
Novo buying Akero for $4.7B to strengthen MASH portfolio - BioWorld MedTech
Why Akero Therapeutics Stock Trounced the Market on Thursday - The Globe and Mail
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $5.2 Billion Buyout - Investor's Business Daily
Novo Nordisk to acquire Akero Therapeutics in $5.2 billion deal to expand MASH treatments - Investing.com Nigeria
What’s Driving The Super Rally In Akero Shares On Thursday Morning? - Stocktwits
Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion By Investing.com - Investing.com Nigeria
With $4.7B Akero Acquisition, Novo Nordisk Maps Out Broader Strategy in MASH and Beyond - MedCity News
Promising Medical Stocks To Watch TodayOctober 9th - MarketBeat
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today - Stocktwits
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akero Therapeutics Inc-Aktie (AKRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rolph Timothy | Chief Scientific Officer |
Oct 07 '25 |
Option Exercise |
28.35 |
12,500 |
354,375 |
179,071 |
| Rolph Timothy | Chief Scientific Officer |
Oct 07 '25 |
Sale |
46.08 |
12,500 |
576,001 |
166,571 |
| Cheng Andrew | President and CEO |
Oct 08 '25 |
Option Exercise |
0.61 |
52,212 |
32,110 |
526,114 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):